Sunday, November 22, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

ImmunityBio Shares Plummet Following FDA Rebuke Over Marketing Claims

Jackson Burston by Jackson Burston
April 3, 2026
in Analysis, Healthcare, Pharma & Biotech
0
ImmunityBio Stock
0
SHARES
71
VIEWS
Share on FacebookShare on Twitter

The biotechnology firm ImmunityBio finds itself caught between significant operational progress and mounting regulatory scrutiny. A recent official warning from the U.S. Food and Drug Administration (FDA) triggered a sharp 21% single-day decline in the company’s stock, erasing nearly $2 billion in market capitalization.

The regulatory action centers on promotional materials for the bladder cancer therapy Anktiva. The FDA has determined that a television advertisement and a podcast featuring Chairman and CEO Dr. Patrick Soon-Shiong were misleading. According to the agency, these materials overstated the drug’s efficacy and promoted unapproved methods of administration, such as subcutaneous injections, while omitting critical safety information. The situation is compounded by the FDA’s assertion that ImmunityBio failed to address two prior warnings issued in 2025 and 2026.

Legal Repercussions Mount for Management

The fallout from the FDA’s reprimand is expanding into the legal arena. The Rosen Law Firm has filed a securities class action lawsuit on behalf of investors who purchased ImmunityBio stock between mid-January and the end of March 2026. The suit alleges the company’s leadership artificially inflated perceptions of Anktiva’s capabilities, thereby creating false market expectations. A lead plaintiff for the case is to be appointed by a California court before the close of May 2026.

Concurrently, ImmunityBio faces a pressing 15-day deadline to submit a comprehensive corrective action plan to the FDA, detailing how it will address the cited violations in its promotional campaigns.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Strong Commercial Performance Provides a Counter-Narrative

Amidst these legal and regulatory challenges, the company’s underlying business tells a different story. ImmunityBio reported 2025 net sales for Anktiva of $113 million, representing a staggering increase of approximately 700% year-over-year. The clinical development program also continues to advance.

Recent milestones include the adoption of the therapy into the National Comprehensive Cancer Network’s treatment guidelines for specific bladder cancer patients. Furthermore, the company has completed patient enrollment for its pivotal QUILT-2.005 clinical trial. Interim results from this study have indicated an improved duration of response for participants.

A Stock Caught Between Two Realities

ImmunityBio’s equity now trades at the intersection of these divergent narratives. The existing drug approvals and a planned regulatory submission for the fourth quarter of 2026 underpin the fundamental business case. However, the weight of regulatory risk and ongoing litigation continues to pressure the stock’s valuation.

In the immediate term, investor attention is fixed on the company’s response to the FDA’s 15-day ultimatum. Management’s ability to present a convincing resolution to the marketing dispute will be a critical test.

Ad

ImmunityBio Stock: Buy or Sell?! New ImmunityBio Analysis from November 21 delivers the answer:

The latest ImmunityBio figures speak for themselves: Urgent action needed for ImmunityBio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 21.

ImmunityBio: Buy or sell? Read more here...

Tags: ImmunityBio
Jackson Burston

Jackson Burston

Related Posts

SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
Münchener Rück Stock
Analysis

Munich Re’s Monte Carlo Warning Collides With Wall Street’s Widest Analyst Split in Years

September 7, 2026
Novo Nordisk Stock
Analysis

Novo Nordisk Faces a New Front: 300-Fold Rise in GLP-1 Scripts for Children Under 12

September 7, 2026
Next Post
Take-Two Stock

Take-Two Shares Gain on Confidence in Blockbuster Game Investment

Oracle Stock

Oracle's Strategic Pivot: A High-Stakes Bet on AI Infrastructure

Strategy Stock

Defying Market Sentiment: Strategy Doubles Down on Bitcoin Accumulation

Recommended

WM stock news

Spire Wealth Management Shows Confidence in Churchill Downs Incorporated with New Acquisition and Bet on Future Growth

3 years ago
Chevron Stock

Chevron Shares Surge Amid Global Oil Supply Disruption

8 months ago
Q2 Holdings Stock

Inclusion in S&P SmallCap 600 Index Ignites Q2 Holdings Stock Rally

1 year ago
REV Stock

REV Group Shares Hit Record High Amid Political Scrutiny

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

Trending

CrowdStrike Stock
Newsletter

93% of Stocks Fall as CrowdStrike Courts Zscaler

by Stephanie Dugan
November 21, 2026
0

Dear readers, The question heading into Friday was whether Anthropic would hold its $83 offer price. It...

Nvidia Stock

Anthropic Lists at a Premium, but the Sell-Off Keeps Going

November 20, 2026
Bitcoin Stock

Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

November 19, 2026
Nvidia Stock

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

November 18, 2026
Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • 93% of Stocks Fall as CrowdStrike Courts Zscaler
  • Anthropic Lists at a Premium, but the Sell-Off Keeps Going
  • Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com